HACE1-mediated NRF2 activation causes enhanced malignant phenotypes and decreased radiosensitivity of glioma cells
Tóm tắt
HACE1, an E3 ubiquitin-protein ligase, is frequently inactivated and has been evidenced as a putative tumor suppressor in different types of cancer. However, its role in glioma remains elusive. Here, we observed increased expression of HACE1 in gliomas related to control subjects, and found a strong correlation of high HACE1 expression with poor prognosis in patients with WHO grade III and IV as well as low-grade glioma (LGG) patients receiving radiotherapy. HACE1 knockdown obviously suppressed malignant behaviors of glioma cells, while ectopic expression of HACE1 enhanced cell growth in vitro and in vivo. Further studies revealed that HACE1 enhanced protein stability of nuclear factor erythroid 2-related factor 2 (NRF2) by competitively binding to NRF2 with another E3 ligase KEAP1. Besides, HACE1 also promoted internal ribosome entry site (IRES)-mediated mRNA translation of NRF2. These effects did not depend on its E3 ligase activity. Finally, we demonstrated that HACE1 dramatically reduced cellular ROS levels by activating NRF2, thereby decreasing the response of glioma cells to radiation. Altogether, our data demonstrate that HACE1 causes enhanced malignant phenotypes and decreased radiosensitivity of glioma cells by activating NRF2, and indicate that it may act as the role of prognostic factor and potential therapeutic target in glioma.
Từ khóa
Tài liệu tham khảo
Louis, D. N. et al. The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131, 803–820 (2016).
Stewart, L. A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359, 1011–1018 (2002).
Yan, Y. et al. Novel function of lncRNA ADAMTS9-AS2 in promoting temozolomide resistance in glioblastoma via upregulating the FUS/MDM2 ubiquitination axis. Front. Cell Dev. Biol. 7, 217 (2019).
Yan, Y. et al. FGFR2-mediated Phosphorylation of PTEN at Tyrosine 240 Contributes to the Radioresistance of Glioma. J. Cell Commun. Signal. 13, 279–280 (2019).
Slade, I. et al. Constitutional translocation breakpoint mapping by genome-wide paired-end sequencing identifies HACE1 as a putative Wilms tumour susceptibility gene. J. Med. Genet. 47, 342–347 (2010).
Zhang, L. et al. The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers. Nat. Med. 13, 1060–1069 (2007).
Torrino, S. et al. The E3 ubiquitin-ligase HACE1 catalyzes the ubiquitylation of active Rac1. Dev. Cell. 21, 959–65 (2011).
Goka, E. T. & Lippman, M. E. Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression. Oncogene 34, 5395–5405 (2015).
Daugaard, M. et al. Hace1 controls ROS generation of vertebrate Rac1-dependent NADPH oxidase complexes. Nat. Commun. 4, 2180 (2013).
Castillo-Lluva, S. et al. The tumour suppressor HACE1 controls cell migration by regulating Rac1 degradation. Oncogene 32, 1735–1742 (2013).
Cheng, G., Diebold, B. A., Hughes, Y. & Lambeth, J. D. Nox1-dependent reactive oxygen generation is regulated by Rac1. J. Biol. Chem. 281, 17718–17726 (2006).
Ueyama, T., Geiszt, M. & Leto, T. L. Involvement of Rac1 in activation of multicomponent Nox1- and Nox3-based NADPH oxidases. Mol. Cell Biol. 26, 2160–2174 (2006).
Liu, Z. et al. Ubiquitylation of autophagy receptor Optineurin by HACE1 activates selective autophagy for tumor suppression. Cancer Cell. 26, 106–120 (2014).
El-Hachem, N. Uncovering and deciphering the pro-invasive role of HACE1 in melanoma cells. Cell Death Differ. 25, 2010–2022 (2018).
Giese, A., Bjerkvig, R., Berens, M. E. & Westphal, M. Cost of of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. 21, 1624–1636 (2003).
Nagendra, K. et al. Low doses of PEG-coated gold nanoparticles sensitize solid tumors to cold plasma by blocking the PI3K/AKT-driven signaling axis to suppress cellular transformation by inhibiting growth and EMT. Biomaterials 87, 118–130 (2016).
Rotblat, B. et al. HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response. Proc. Natl Acad. Sci. USA 111, 3032–3037 (2014).
Sukumari-Ramesh, S., Prasad, N., Alleyne, C. H., Vender, J. R. & Dhandapani, K. M. Overexpression of Nrf2 attenuates Carmustine-induced cytotoxicity in U87MG human glioma cells. BMC Cancer 15, 118 (2015).
Lu, D. Y. et al. Osteopontin increases heme oxygenase-1 expression and subsequently induces cell migration and invasion in glioma cells. Neuro-Oncol. 14, 1367–1378 (2012).
Ohta, T. et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 68, 1303–1309 (2008).
Li, W. et al. An internal ribosomal entry site mediates redox-sensitive translation of Nrf2. Nucleic Acids Res. 38, 778–788 (2010).
Hellen, C. U. & Sarnow, P. Internal ribosome entry sites in eukaryotic mRNA molecules. Genes Dev. 15, 1593–1612 (2001).
Zhang, J., Dinh, T. N., Kappeler, K., Tsaprailis, G. & Chen, Q. M. La autoantigen mediates oxidant induced de novo Nrf2 protein translation. Mol. Cell Proteom. 11, M111.015032 (2012).
Kapsogeorgou, E. K., Gourzi, V. C. & Manoussakis, M. N. Cellular microRNAs (miRNAs) and Sjogren’s syndrome: candidate regulators of autoimmune response and autoantigen expression. J. Autoimmun. 37, 129–135 (2011).
Knitter, J. R. et al. Interval change in diffusion and perfusion MRI parameters for the assessment of pseudoprogression in cerebral metastases treated with stereotactic radiation. AJR 211, 168–175 (2018).
Yun, T. J. et al. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging. Radiology 274, 830–840 (2015).
Nguyen, T., Nioi, P. & Pickett, C. B. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 284, 13291–13295 (2009).
McDonald, J. T. et al. Ionizing radiation activates the Nrf2 antioxidant response. Cancer Res. 70, 8886–8895 (2010).
Wang, T. et al. Role of Nrf2 signaling pathway in the radiation tolerance of patients with head and neck squamous cell carcinoma: an in vivo and in vitro study. Onco. Targets Ther. 10, 1809–1819 (2017).
Thangamani, S. et al. Ebselen exerts antifungal activity by regulating glutathione (GSH) and reactive oxygen species (ROS) production in fungal cells. Biochim. Biophys. Acta Gen. Subj. 1861, 3002–3010 (2017).
Roh, J. L., Kim, E. H., Jang, H. & Shin, D. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 11, 254–262 (2017).
Zhu, J. et al. Nrf2 is required to maintain the self-renewal of glioma stem cells. BMC Cancer 13, 380 (2013).
Liang, C. et al. Sjogren syndrome antigen B (SSB)/La promotes global microRNA expression by binding microRNA precursors through stem-loop recognition. J. Biol. Chem. 288, 723–736 (2013).
Jayakumar, S., Kunwar, A., Sandur, S. K., Pandey, B. N. & Chaubey, R. C. Differential response of DU145 and PC3 prostate cancer cells to ionizing radiation: role of reactive oxygen species, GSH and Nrf2 in radiosensitivity. Biochim. Biophys. Acta 1840, 485–494 (2014).
Zhou, S., Ye, W., Shao, Q., Zhang, M. & Liang, J. Nrf2 is a potential therapeutic target in radioresistance in human cancer. Crit. Rev. Oncol. Hematol. 88, 706–715 (2013).
Sekhar, K. R. & Freeman, M. L. Nrf2 promotes survival following exposure to ionizing radiation. Free Radic. Biol. Med. 88, 268–274 (2015).
Ma, X., Wang, M., Yin, T., Zhao, Y. & Wei, X. Myeloid-derived suppressor cells promote metastasis in breast cancer after the stress of operative removal of the primary cancer. Front. Oncol. 9, 855 (2019).
Shi, J. et al. Increased expression of EHF via gene amplification contributes to the activation of HER family signaling and associates with poor survival in gastric cancer. Cell Death Dis. 7, 2442 (2016).
Jason, K. S. et al. Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma. Genome Biol. 21, 216 (2020).
Li, Y. et al. ZNF677 suppresses Akt phosphorylation and tumorigenesis in thyroid cancer. Cancer Res. 78, 5216–5228 (2018).
Li, Y. et al. c-Myc is a major determinant for antitumor activity of aurora A kinase inhibitor MLN8237 in thyroid cancer. Thyroid 28, 1642–1654 (2018).
Prudnikova, T. Y., Villamar-Cruz, O., Rawat, S. J., Cai, K. Q. & Chernoff, J. Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells. Oncogene 35, 2178–2185 (2016).
Wei, J. et al. Increased expression of NAF1 contributes to malignant phenotypes of glioma cells through promoting protein synthesis and associates with poor patient survival. Oncogenesis 8, 25 (2019).
Zhang, Z. et al. Repurposing brigatinib for the treatment of colorectal cancer based on inhibition of ER-phagy. Theranostics 9, 4878–4892 (2019).
Dang, S. et al. Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis. Oncogene 38, 4804–4819 (2019).
Xi, R. et al. HPV16 E6-E7 induces cancer stem-like cells phenotypes in esophageal squamous cell carcinoma through the activation of PI3K/Akt signaling pathway in vitro and in vivo. Oncotarget 7, 57050–57065 (2016).
Hormuth, D. A., Skinner, J. T., Does, M. D. & Yankeelov, T. E. A comparison of individual and population-derived vascular input functions for quantitative DCE-MRI in rats. Magn. Reson. Imaging 32, 397–401 (2014).
Zhao, J., Yang, Z. Y., Luo, B. N., Yang, J. Y. & Chu, J. P. Quantitative evaluation of diffusion and dynamic contrast-enhanced MR in tumor parenchyma and peritumoral area for distinction of brain tumors. PLoS ONE 10, e0138573 (2015).